A number of national and international organizations are advocating more intensive screening for Chlamydia trachomatis and Neisseria gonorrhoeae in high-prevalence populations as a way to reduce the prevalence of these infections. In this article, we review the available evidence and conclude that there is a paucity of evidence to support this approach. We further hypothesize that increasing screening intensity in high-prevalence populations will result in a considerable risk for the emergence of antimicrobial resistance in Neisseria gonorrhoeae and other pathobionts.
The recent emergence of combined high-level resistance to azithromycin and ceftriaxone in Neisseria gonorrhoeae (Ng) [1] should be seen in the context of a wider epidemic of antimicrobial resistance (AMR) that is predicted to result in up to 300 million premature deaths by 2050 [2] . An abundance of evidence from in vitro studies and individual-and population-level analyses have established that the key driver of this AMR is high levels of antimicrobial consumption [2] [3] [4] . As a result, the prudent and restricted use of antimicrobials has become a central pillar of efforts to combat the spread of AMR [2, 5] . A range of studies have confirmed that restricting antimicrobial consumption to below certain thresholds dramatically reduces the emergence of AMR in a range of organisms [3, 4] . Two recent studies have found that the prevalence of AMR is correlated with the prevalence of antimicrobial consumption in the general population for both Ng and Treponema pallidum subsp. pallidum [6, 7] . In addition, ecological studies have found some evidence of an association between the prevalence of AMR in Ng in men who have sex with men (MSM) and the intensity of screening for Ng/Chlamydia trachomatis (Ct) in this population [8, 9] .
In this article, we argue that concerns about the induction of AMR need to be taken into account before we expand screening for Ng and Ct in high-sexually transmitted infection (STI)-prevalence populations, as is currently advocated by a number of organizations and guidelines [10] [11] [12] .
THE CASE FOR NG/CT SCREENING
Advocates of screening for Ng/Ct have argued that this strategy offers a number of potential benefits, such as reducing the prevalence of these infections, reducing the risk of pelvic inflammatory disease/infertility and engaging highrisk individuals in care [13] [14] [15] . The Word Health Organization's global 'Towards Ending STIs' strategy for 2016-2021, for example, advocates widespread screening as a key component of its strategy to reduce the incidence of Ct and Ng by 90 % between 2016 and 2030 [12] . The argument used is that, because the majority of Ng/Ct infections in a population are asymptomatic, screening asymptomatic individuals is vital to break the 'chain of STI transmission'. It is further argued that screening will be particularly important in higher-STI-prevalence populations if we are to reach the 90 % target. A similar logic has been used to promote more frequent Ng/Ct screening in MSM. Guidelines for HIV PrEP programmes, for example, now frequently advocate three-site, 3-monthly Ng/Ct (3Â3) screening [10, 11] . Systematic reviews of the available evidence suggest that screening for Ct in women is associated with a reduction in the risk of pelvic inflammatory disease and possibly Ct prevalence [14, 15] . The Cochrane systematic review included two controlled trials investigating the effect of screening on Ct prevalence [14] . One large controlled trial from the Netherlands found that screening had no effect on Ct prevalence in the general population [16] . Another cluster randomized controlled trial (RCT) found that 'screening' resulted in a reduction in Ct prevalence in Peruvian sex workers. However, this reduced prevalence resulted from a multicomponent intervention and thus it is difficult to know whether the screening was responsible for the change in prevalence [13, 14] . A recent cluster RCT found that enhanced Ct screening had no effect on Ct prevalence in Australian primary health centres [17] . No RCTs have been conducted in women from the general population in countries with high STI prevalence [15] . In the two systematic reviews, no evidence was found for a benefit from Ct in men and no RCTs were discovered that assessed the benefits of Ng screening [14, 15] .
Does screening reduce Ng/Ct prevalence in MSM?
In the absence of RCTs in MSM, our group conducted a systematic review of observational studies investigating the effect of Ng/Ct screening on the prevalence of these infections in MSM. We found no evidence that screening was associated with a reduction in prevalence [18] . Even in PrEP studies where all participants received 3Â3 screening, and treatment if testing positive, the prevalence of Ng and Ct remained unchanged at around 10 % for each. These findings are not too surprising given the density of PrEP participants' sexual networks. In the i-Prex PREP study, for example, participants reported a mean of 18 partners (SD ±35) in the preceding 90 days [19] . This high rate of partner change generates a dense sexual network that sustains the high prevalence of Ng, Ct and other STIs [20] . It is thus possible that screening for Ng/Ct in high-sexual-network-connectivity settings such as MSM PrEP populations may have little effect on the prevalence of these infections.
Three reasons why enhanced Ng/Ct screening may drive AMR in MSM In addition, three considerations suggest that screening in these settings may be an important driver of AMR. Firstly, screening results in 15-20 % of PrEP recipients being diagnosed with Ng/Ct at each 3-monthly visit [18, 19] . If they receive treatment for all these infections, then the resulting antimicrobial exposure will be considerably larger than that which has been established to lead to macrolide resistance in a range of bacterial pathobionts [21] . Secondly, as illustrated in Fig. 1 , persons who are screened and treated for Ng typically return to the same local sexual network where they are at high risk for reinfection with Ng, but at a time when, by virtue of their recent azithromycin/ceftriaxone treatment, their resistomes are enriched with genes conferring resistance to these antimicrobials. If the reinfecting Ng is able to take up these genes via transformation, this will provide it with a fitness advantageparticularly in the setting of continued high antimicrobial Fig. 1 . High network connectivity combined with antibiotic exposure from screening could produce antimicrobial resistance -a schematic illustration [1] . High/low sexual network connectivity translate into a high/low equilibrium prevalence of N. gonorrhoeae in January (Ng; red squares). [2] Active screening of 25 % of this population (black bordered squares) results in a lower Ng prevalence in April, but at the expense of an altered resistome (yellow squares represent individuals with Ng cleared via antibiotics in the past 3 months). Because the network connectivity remains unchanged, Ng tends to return to its equilibrium prevalence. This places recently cured individuals (such as individual 'B') at high risk of reinfection at a time when their resistomes are enriched with resistance genes. Early Ng reinfections are able to take up these resistance genes via transformation. In a setting of high exposure to antibiotics these less susceptible Ng strains will have a fitness advantage over more susceptible strains. [3] These dynamics would be predicted to favour the emergence and spread of resistant Ng. (Uninfected individuals, grey squares; the edges between squares represent sexual relationships).
pressure. If the underlying network connectivity and antimicrobial pressure are unaltered, the Ng prevalence would be predicted to return to its baseline prevalence via the selection and spread of the resistant strains of Ng. Thirdly, there is some ecological-level evidence that AMR is more likely to emerge in more-compared to less-intensely screened MSM populations [8, 9] .
These considerations generate the hypothesis that intense Ng/Ct screening in MSM is having little or no effect on the prevalence of Ng/Ct, but that it is placing a significant selection pressure on the development of AMR.
High-risk heterosexual populations
A similar argument could apply to high-network-connectivity heterosexual populations. AMR in Ng has typically first emerged in core groups such as MSM with high rates of partner change and sex workers with high rates of antimicrobial consumption, such as those in certain Asian populations [22] . AMR has not, however, typically emerged in other heterosexual populations with dense sexual networks, such as certain populations in sub-Saharan Africa that have had high prevalence rates of Ng, Ct, syphilis, HSV-2 and HIV for decades but where antimicrobial consumption rates, until relatively recently, have not been high [5, 23, 24] . We hypothesize that intense Ng/Ct screening in these populations could result in a significant pressure for the selection of AMR in these populations with or without a reduction in the prevalence of these infections. Whilst such a strategy may still be considered to be beneficial if it can be shown that it results in a reduction in serious Ng/Ct sequelae, this benefit still needs to be established empirically. In addition, these benefits would need to be weighed against the negative effects, such as the induction of AMR.
As illustrated in Fig. 1 , the prevalence of Ng in lowconnectivity populations is so low (<0.1 % in the general heterosexual population in the United Kingdom [25] ) that even intensive screening is unlikely to result in sufficient antibiotic exposure to provide Ng access to resistance genes or a fitness advantage for resistance strains. Intensive screening in these settings would thus be expected to generate a low risk of inducing AMR. This generates a prevention paradox: whilst screening for Ng/Ct in high-STI-prevalence populations may be critical to reducing the global prevalence of these infections, this strategy constitutes a high risk of inducing AMR. Thus whereas the prevalence of Ng/Ct in low-network-connectivity populations may be too low to make screening cost-effective, the prevalence in high-connectivity populations may be so resiliently high that intense screening risks AMR induction. In these circumstances, the net benefits of screening may be limited mainly to sub-populations such as those exiting high-connectivity networks (e.g. two individuals who transition from multiple partnering to monogamy) or an individual whose partner, but not themselves, engages in higher-risk activities.
CONCLUSION
A number of criteria should be met before a screening programme can be introduced [26] . These include that the screening program should be cost-effective [26] . The limited evidence for the efficacy of screening for Ct comes from studies in low-network-connectivity populations [14] . No RCTs have assessed the efficacy of Ng screening or Ct screening in high-network-connectivity populations such as PrEP cohorts and high-STI-prevalence populations in sub-Saharan Africa. Given the hypothesis that the risk of screening-induced AMR is considerably higher in high-compared to low-networkconnectivity populations, RCTs are urgently required to assess the net benefits and risks of enhanced Ng/Ct screening strategies in these populations and defined sub-populations. In the interim, it would be prudent for programmes that include enhanced Ng/Ct screening in high-connectivity populations to monitor the effects on antimicrobial consumption and resistance rates in STIs and commensal organisms.
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